Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850242 | 0.87 | KDM4E (0.41) | CD44KDM4EASPHKDM8TSHR | |
| SCHEMBL30039362 | 0.85 | KDM4E (0.41) | KDM4EASPHKDM8TSHRBLM | |
| SCHEMBL29848830 | 0.76 | NOS3 (0.47) | KDM4EASPHKDM8TSHRBLM | |
| SCHEMBL16651284 | 0.76 | NOS3 (0.47) | KDM4EASPHKDM8TSHRBLM | |
| SCHEMBL29189076 | 0.75 | NOS3 (0.50) | KDM4EASPHKDM8TSHRBLM | |
| SCHEMBL1592979 | 0.73 | NOS3 (0.56) | CD44PNMTMAOB | |
| SCHEMBL19153131 | 0.73 | CD44 (0.44) | CD44PNMTMAOB | |
| SCHEMBL16784815 | 0.73 | CD44 (0.44) | CD44PNMTMAOB | |
| SCHEMBL20445879 | 0.72 | CD44 (0.41) | CD44KDM4EALDH1A1L3MBTL1PNMT | |
| SCHEMBL4984720 | 0.72 | TSHR (0.33) | TSHRBLMSLC6A1SLC6A13GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881825-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | VACCA JOSEPH P (US) | 2013-07-11 | — | — | US | disclosed |
| US-8293731-B2 | HIV integrase inhibitors | Merck Sharp + Dohme Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | SCHERING CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-7968564-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-7741315-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| EP-1881825-A2 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006121831-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087767-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054399-A1 | HIV INTEGRASE INHIBITORS | REV1, POLR1A, POLR2H | CD44 4514/4885KDM4E 1580/4885ASPH 1634/4885 |
| US-20100204201-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | CD44 4453/4885KDM4E 1556/4885ASPH 1618/4885 |
| US-20130178468-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | CD44 4453/4885KDM4E 1556/4885ASPH 1618/4885 |
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | CD44 2168/4885KDM4E 1932/4885ASPH 923/4885 |
| US-20110275621-A1 | HIV INTEGRASE INHIBITORS | REV1, CDKN1A, CCNI | CD44 4453/4885KDM4E 1556/4885ASPH 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.